The identification of glucagon-like peptide-1 (GLP-1), belonging to the family of gut-derived incretin hormones, paved the way years ago to the development of GLP-1 RAs, with the intention of enlarging the armamentarium of therapeutic options for T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.